Since tyrosine kinases play crucial roles in cellular proliferation, growth, differentiation and other life-sustaining processes, while both B cells and myeloid cells (particularly microglia) are important drivers of MS progression [42], BTK inhibitors were suggested as potential candidates for the treatment of MS and being investigated in phase 2/3 clinical trials. The gene discussed is BTK; the disease is myeloid sarcoma.